

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1653HXP

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	DEC 05	CASREACT(R) - Over 10 million reactions available
NEWS	4	DEC 14	2006 MeSH terms loaded in MEDLINE/IMEDLINE
NEWS	5	DEC 14	2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS	6	DEC 14	CA/Caplus to be enhanced with updated IPC codes
NEWS	7	DEC 21	IPC search and display fields enhanced in CA/Caplus with the IPC reform
NEWS	8	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/USPAT2
NEWS	9	JAN 13	IPC 8 searching in IFIPAT, IFIUDb, and IFICDB
NEWS	10	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS	11	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS	12	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS	13	JAN 30	Saved answer limit increased
NEWS	14	JAN 31	Monthly current-awareness alert (SDI) frequency added to TULSA
NEWS	15	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS	16	FEB 22	Status of current WO (PCT) information on STN
NEWS	17	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS	18	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS	19	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	20	FEB 28	MEDLINE/IMEDLINE reload improves functionality
NEWS	21	FEB 28	TOXCENTER reloaded with enhancements
NEWS	22	FEB 28	REGISTRY/ZREGISTRY enhanced with more experimental spectral property data
NEWS	23	MAR 01	INSPEC reloaded and enhanced
NEWS	24	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS	25	MAR 08	X.25 communication option no longer available after June 2006
NEWS EXPRESS			FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT http://download.cas.org/express/v8.0-Discover/
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:20:48 ON 12 MAR 2006

=> file medline, uspatful, dgene, embase, biosis, biotechds, fsta, jicst,		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 12:21:10 ON 12 MAR 2006

FILE 'USPATFULL' ENTERED AT 12:21:10 ON 12 MAR 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 12:21:10 ON 12 MAR 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'EMBASE' ENTERED AT 12:21:10 ON 12 MAR 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 12:21:10 ON 12 MAR 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'BIOTECHDS' ENTERED AT 12:21:10 ON 12 MAR 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'FSTA' ENTERED AT 12:21:10 ON 12 MAR 2006
COPYRIGHT (C) 2006 International Food Information Service

FILE 'JICST-EPLUS' ENTERED AT 12:21:10 ON 12 MAR 2006
COPYRIGHT (C) 2006 Japan Science and Technology Agency (JST)

=> s (TLR8 agonist)
L1 16 (TLR8 AGONIST)

=> d l1 ti abs ibib tot

L1 ANSWER 1 OF 16 MEDLINE on STN
TI Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults.
AB Resiquimod is a Toll-like receptor 7 (TLR7) and **TLR8 agonist** that is a potent inducer of alpha interferon (IFN-alpha) and other cytokines. The effects of multiple applications of resiquimod gel were assessed in a randomized, single-blind, dose-ranging, placebo-controlled study with 41 healthy subjects. Over a 3-week period, 1-g doses of resiquimod or vehicle gel (3:1 randomization) were applied to a 50-cm2 area of the upper arm according to the following regimens: 0.25% applied for 8 h two times per week, 0.05% applied for 8 h two times per week, 0.05% applied for 8 h three times per week, and 0.01% applied for 24 h three times per week. Skin biopsy specimens were obtained prior to the application of the first dose and after the completion of application of the last dose. Dosing with 0.01 and 0.05% resiquimod was well tolerated, but that with 0.25% was not; a dose-response relationship for local adverse effects was observed. The level of systemic exposure during multiple topical dosings was <1% of the applied dose. A significant increase in responders after completion of application of the last dose was observed for serum IFN and the interleukin-1 (IL-1) receptor

antagonist ($P < 0.01$, Fisher's exact test). Increased levels of mRNA for IL-6, IL-8, IFN-alpha, and Mx (an IFN-alpha-inducible protein) were seen in posttreatment biopsy specimens from the group receiving 0.25% resiquimod compared to the levels seen in specimens from the group receiving vehicle only ($P < 0.01$, Wilcoxon rank sum test). A dose-response-related increase in CD3-positive cells consistent with T-lymphocyte infiltration and a decrease in CD1a-positive cells, consistent with emigration of Langerhans' cells, were observed in treated skin. This study suggests that resiquimod is a potent topically active immune response modifier that significantly enhances the cutaneous immune response.

ACCESSION NUMBER: 2003556531 MEDLINE
DOCUMENT NUMBER: PubMed ID: 14638493
TITLE: Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults.
AUTHOR: Sauder Daniel N; Smith Michael H; Senta-McMillian Therese; Soria Inmaculada; Meng Tze-Chiang
CORPORATE SOURCE: Department of Dermatology, University of Toronto School of Medicine, Toronto, Ontario, Canada.
SOURCE: Antimicrobial agents and chemotherapy, (2003 Dec) Vol. 47, No. 12, pp. 3846-52.
Journal code: 0315061. ISSN: 0066-4804.
PUB. COUNTRY: United States
DOCUMENT TYPE: (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200401
ENTRY DATE: Entered STN: 20031126
Last Updated on STN: 20040114
Entered Medline: 20040113

L1 ANSWER 2 OF 16 USPATFULL on STN

TI Enhancement of immune responses

AB The present invention provides methods for enhancing the immune responses induced by IRM compounds. Generally, the methods include administering a cytokine receptor agonist or a cytokine inducer prior to administering an IRM compound to a cell population.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:275172 USPATFULL
TITLE: Enhancement of immune responses
INVENTOR(S): Miller, Richard L., Maplewood, MN, UNITED STATES
Tomai, Mark A., Woodbury, MN, UNITED STATES
PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005239735	A1	20051027
APPLICATION INFO.:	US 2004-27037	A1	20041230 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-533143P	20031230 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427, US	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
LINE COUNT:	864	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 3 OF 16 USPATFULL on STN

TI Sequence requirements for inhibitory oligonucleotides

AB Novel oligonucleotides having immune inhibitory effects, and methods for their use, are provided. The inhibitory oligonucleotides include those that specifically inhibit certain Toll-like receptors, including TLR7, TLR8, and TLR9. Certain of the immunoinhibitory oligonucleotides inhibit a combination of TLRs selected from TLR7, TLR8, and TLR9. Inhibitors of TLR9 are characterized by a 5' CC dinucleotide appropriately spaced upstream of a G-rich oligomer. Inhibitors of TLR8 include specific simple dinucleotides and oligonucleotides ending at their 3' termini with the specific dinucleotides. TLR7 inhibitors include oligonucleotides having a phosphorothioate backbone. Also provided are combinations and conjugates involving the inhibitory oligonucleotides of the invention and other agents, where the other agents include TLR agonists and antigens. Compositions of the invention can be used to shape an immune response, reduce unwanted specific TLR-mediated immunostimulation, and to treat conditions including allergy, asthma, infection, and cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:275170 USPATFULL

TITLE: Sequence requirements for inhibitory oligonucleotides

INVENTOR(S): Jurk, Marion, Duesseldorf, GERMANY, FEDERAL REPUBLIC OF
Vollmer, Jorg, Duesseldorf, GERMANY, FEDERAL REPUBLIC OF
Krieg, Arthur M., Wellesley, MA, UNITED STATES
Uhlmann, Eugen, Glashuetten, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): Coley Pharmaceutical GmbH, Langenfeld, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
Coley Pharmaceutical Group, Inc., Wellesley, MA, UNITED STATES (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005239733	A1	20051027
APPLICATION INFO.:	US 2004-977560	A1	20041029 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-516221P	20031031 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE, BOSTON, MA, 02210-2211, US	
NUMBER OF CLAIMS:	46	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	3753	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 4 OF 16 USPATFULL on STN

TI Therapeutic combinations and methods including IRM compounds

AB The present invention provides therapeutic combinations that include an immune response modifier (IRM) component and an anti-inflammatory component. The inventions further provide methods of treating a condition by administering to one having the condition a therapeutic combination that includes an IRM component and an anti-inflammatory component.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:260857 USPATFULL
 TITLE: Therapeutic combinations and methods including IRM compounds
 INVENTOR(S): Tomai, Mark A., Woodbury, MN, UNITED STATES
 Gullikson, Gary W., Stillwater, MN, UNITED STATES
 Hammerbeck, David M., Houlton, WI, UNITED STATES
 Egging, Elaine A., Woodbury, MN, UNITED STATES
 Reiter, Michael J., New Richmond, WI, UNITED STATES
 Gram, Christopher D., River Falls, WI, UNITED STATES
 Vasilakos, John P., Woodbury, MN, UNITED STATES
 Alkan, Sefik S., Woodbury, MN, UNITED STATES
 PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005226878	A1	20051013
APPLICATION INFO.:	US 2005-142045	A1	20050601 (11)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2004-1979, filed on 2 Dec 2004, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-526240P	20031202 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427, US	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	1254	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L1 ANSWER 5 OF 16 USPATFULL on STN

TI Therapeutic combinations and methods including IRM compounds
 AB The present invention provides therapeutic combinations that include an immune response modifier (IRM) component and an anti-inflammatory component. The inventions further provide methods of treating a condition by administering to one having the condition a therapeutic combination that includes an IRM component and an anti-inflammatory component.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:196929 USPATFULL
 TITLE: Therapeutic combinations and methods including IRM compounds
 INVENTOR(S): Tomai, Mark A., Woodbury, MN, UNITED STATES
 Gullikson, Gary W., Stillwater, MN, UNITED STATES
 Hammerbeck, David M., Houlton, WI, UNITED STATES
 Egging, Elaine A., Woodbury, MN, UNITED STATES
 Reiter, Michael J., New Richmond, WI, UNITED STATES
 Gram, Christopher D., River Falls, WI, UNITED STATES
 Vasilakos, John P., Woodbury, MN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005171072	A1	20050804
APPLICATION INFO.:	US 2004-1979	A1	20041202 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-526240P	20031202 (60)
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: 3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST.
PAUL, MN, 55133-3427, US
NUMBER OF CLAIMS: 64
EXEMPLARY CLAIM: 1
LINE COUNT: 1237
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 6 OF 16 USPATFULL on STN
TI Immunomodulatory combinations
AB The present invention provides immunomodulatory combinations that includes an IRM component and a therapeutic agent, each in an amount that, when in combination with the other, is effective for inducing an immune response in a subject.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:182942 USPATFULL
TITLE: Immunomodulatory combinations
INVENTOR(S): Hammerbeck, David M., Houlton, WI, UNITED STATES
Kedl, Ross M., Denver, CO, UNITED STATES
Miller, Richard L., Maplewood, MN, UNITED STATES
Tomai, Mark A., Woodbury, MN, UNITED STATES
Vasilakos, John P., Woodbury, MN, UNITED STATES
PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005158325	A1	20050721
APPLICATION INFO.:	US 2004-26457	A1	20041230 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-533179P	20031230 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427, US	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	3639	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 7 OF 16 USPATFULL on STN
TI Selective modulation of TLR gene expression
AB The present invention provides a method of identifying a compound that selectively modulates expression of at least one TLR gene. Generally, the method includes providing an assay to detect expression of each of a plurality of TLR genes; performing each assay using a test compound; and identifying the test compound as a compound that selectively modulates expression of at least one TLR gene if the test compound modulates expression of a first TLR gene to a different extent than it modulates expression of at least one second TLR gene. In certain embodiments, the present invention provides compounds identified by a method described above, salts thereof, and pharmaceutical compositions including such compounds, pharmaceutically acceptable forms thereof, derivatives thereof, or pro-drugs thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:68933 USPATFULL
TITLE: Selective modulation of TLR gene expression
INVENTOR(S): Birmachu, Woubalem M. R., St. Anthony Village, MN,
UNITED STATES

Burger, Marla J. C., Woodbury, MN, UNITED STATES
Gleason, Raymond M., Eagan, MN, UNITED STATES
Hanten, John A., Cottage Grove, MN, UNITED STATES
Jin, Jizhong, Vadnais Heights, MN, UNITED STATES
PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005059072	A1	20050317
APPLICATION INFO.:	US 2004-944291	A1	20040917 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-503566P	20030917 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	1133	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L1 ANSWER 8 OF 16 USPATFULL on STN
TI Treatment for CD5+ B cell lymphoma
AB The present invention provides methods for increasing expression of cell surface molecules of CD5.sup.+ B cell lymphoma cells by contacting cells with immune response modifiers. The invention also provides methods for the treatment of CD5.sup.+ B cell lymphomas, including chronic lymphocytic leukemia and small lymphocytic lymphoma, by administering immune response modifier compounds to a subject in need of such treatment. Suitable immune response modifier compounds include agonists of TLR7 and/or TLR8.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2005:63623 USPATFULL
TITLE: Treatment for CD5+ B cell lymphoma
INVENTOR(S): Miller, Richard L., Maplewood, MN, UNITED STATES
Spaner, David E., Toronto, CANADA
PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005054665	A1	20050310
APPLICATION INFO.:	US 2004-933594	A1	20040903 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-500478P	20030905 (60)
	US 2004-561440P	20040412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427	
NUMBER OF CLAIMS:	67	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Page(s)	
LINE COUNT:	1365	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L1 ANSWER 9 OF 16 USPATFULL on STN
TI Immunostimulatory combinations and treatments

AB The present invention provides immunostimulatory combinations and methods. Generally, the immunostimulatory combinations include a topical formulation of an IRM compound and a pharmaceutical composition. Generally, the methods include administering (a) a topical formulation of an IRM compound, and (b) a pharmaceutical composition to an administration site of a subject.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:56161 USPATFULL
TITLE: Immunostimulatory combinations and treatments
INVENTOR(S): Kedl, Ross M., Denver, CO, UNITED STATES
Tomai, Mark A., Woodbury, MN, UNITED STATES
Vasilakos, John P., Woodbury, MN, UNITED STATES
PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005048072	A1	20050303
APPLICATION INFO.:	US 2004-925473	A1	20040825 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-497628P	20030825 (60)
	US 2003-524213P	20031121 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427	
NUMBER OF CLAIMS:	75	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	1097	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 10 OF 16 USPATFULL on STN

TI Methods of treating pulmonary fibrotic disorders

AB The present invention provides methods of treating airway remodeling, the methods generally involve administering an effective amount of a Toll-like receptor agonist to an individual suffering from airway remodeling. The present invention provides methods of treating pulmonary fibrosis, the methods generally involving administering an effective amount of a Toll-like receptor agonist to an individual in need thereof. The present invention further provides pharmaceutical compositions comprising a TLR agonist and a formulation suitable for delivery by inhalation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:315161 USPATFULL
TITLE: Methods of treating pulmonary fibrotic disorders
INVENTOR(S): Raz, Eyal, Del Mar, CA, UNITED STATES
Broide, David, San Diego, CA, UNITED STATES
Takabayashi, Kenji, San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004248837	A1	20041209
APPLICATION INFO.:	US 2003-697817	A1	20031029 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-423035P	20021101 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

LEGAL REPRESENTATIVE: BOZICEVIC, FIELD & FRANCIS LLP, 1900 UNIVERSITY AVE,
SUITE 200, EAST PALO ALTO, CA, 94303
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 2304
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 11 OF 16 USPATFULL on STN
TI Selective modulation of TLR-mediated biological activity
AB Methods of identifying a compound that selectively modulates at least one TLR-mediated cellular activity are disclosed. Generally, the methods include identifying a compound as a compound that selectively modulates at least one TLR-mediated cellular activity if the compound modulates one TLR-mediated cellular activity to a different extent than it modulates a second TLR-mediated cellular activity. Compounds so identified and pharmaceutical compositions including such compounds are also disclosed. Methods of selectively modulating immune cells and methods of treating certain conditions are also provided. Such methods include administering to cells or a subject a compound that selectively modulates a TLR-mediated cellular activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:221317 USPATFULL
TITLE: Selective modulation of TLR-mediated biological activity
INVENTOR(S): Fink, Jason R., Eagan, MN, UNITED STATES
Gorden, Keith B., Maplewood, MN, UNITED STATES
Gorski, Kevin S., White Bear Lake, MN, UNITED STATES
Gupta, Shalley K., Woodbury, MN, UNITED STATES
Qiu, Xiaohong, Rosemount, MN, UNITED STATES
Vasilakos, John P., Woodbury, MN, UNITED STATES
PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004171086	A1	20040902
APPLICATION INFO.:	US 2004-788731	A1	20040227 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-450484P	20030227 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427	
NUMBER OF CLAIMS:	55	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	1870	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 12 OF 16 USPATFULL on STN
TI Methods and compositions related to IRM compounds and toll-like receptor 8
AB Methods of eliciting a TLR8-mediated cellular response are disclosed. Such methods include administration of either a **TLR8 agonist** or a TLR8 antagonist to an IRM-responsive cell so that the IRM compound affects at least one TLR8-mediate cellular signaling pathway. In some cases, the method may provide prophylactic or therapeutic treatment for a condition treatable by modulating a TLR8-mediated cellular pathway.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:209875 USPATFULL
TITLE: Methods and compositions related to IRM compounds and
toll-like receptor 8
INVENTOR(S): Gorden, Keith B., Maplewood, MN, UNITED STATES
Qiu, Xiaohong, Rosemount, MN, UNITED STATES
Vasilakos, John P., Woodbury, MN, UNITED STATES
PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004162309	A1	20040819
APPLICATION INFO.:	US 2004-777310	A1	20040212 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-447179P	20030213 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	1684	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 13 OF 16 USPATFULL on STN
TI Immunostimulatory combinations
AB The present invention provides immunostimulatory combinations.
Generally, the immunostimulatory combinations include a TLR agonist and
a TNF/R agonist. Certain immunostimulatory combinations also may include
an antigen.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:184067 USPATFULL
TITLE: Immunostimulatory combinations
INVENTOR(S): Noelle, Randolph J., Plainfield, NH, UNITED STATES
Ahonen, Cory L., Hanover, NH, UNITED STATES
Kedl, Ross M., Roseville, MN, UNITED STATES
PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004141950	A1	20040722
APPLICATION INFO.:	US 2003-748010	A1	20031230 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-437398P	20021230 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427	
NUMBER OF CLAIMS:	57	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Page(s)	
LINE COUNT:	1355	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 14 OF 16 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
reserved on STN
TI Randomized, Single-Blind, Placebo-Controlled Study of Topical Application

of the Immune Response Modulator Resiquimod in Healthy Adults.
AB Resiquimod is a Toll-like receptor 7 (TLR7) and **TLR8 agonist** that is a potent inducer of alpha interferon (IFN- α) and other cytokines. The effects of multiple applications of resiquimod gel were assessed in a randomized, single-blind, dose-ranging, placebo-controlled study with 41 healthy subjects. Over a 3-week period, 1-g doses of resiquimod or vehicle gel (3:1 randomization) were applied to a 50-cm(2) area of the upper arm according to the following regimens: 0.25% applied for 8 h two times per week, 0.05% applied for 8 h two times per week, 0.05% applied for 8 h three times per week, and 0.01% applied for 24 h three times per week. Skin biopsy specimens were obtained prior to the application of the first dose and after the completion of application of the last dose. Dosing with 0.01 and 0.05% resiquimod was well tolerated, but that with 0.25% was not; a dose-response relationship for local adverse effects was observed. The level of systemic exposure during multiple topical dosings was <1% of the applied dose. A significant increase in responders after completion of application of the last dose was observed for serum IFN and the interleukin-1 (IL-1) receptor antagonist ($P < 0.01$, Fisher's exact test). Increased levels of mRNA for IL-6, IL-8, IFN- α , and Mx (an IFN- α -inducible protein) were seen in posttreatment biopsy specimens from the group receiving 0.25% resiquimod compared to the levels seen in specimens from the group receiving vehicle only ($P < 0.01$, Wilcoxon rank sum test). A dose-response-related increase in CD3-positive cells consistent with T-lymphocyte infiltration and a decrease in CD1a-positive cells, consistent with emigration of Langerhans' cells, were observed in treated skin. This study suggests that resiquimod is a potent topically active immune response modifier that significantly enhances the cutaneous immune response.

ACCESSION NUMBER: 2003493058 EMBASE
TITLE: Randomized, Single-Blind, Placebo-Controlled Study of Topical Application of the Immune Response Modulator Resiquimod in Healthy Adults.
AUTHOR: Sauder D.N.; Smith M.H.; Senta-McMillian T.; Soria I.; Meng T.-C.
CORPORATE SOURCE: T.-C. Meng, 3M Pharmaceuticals, 3M Center, Saint Paul, MN 55144-1000, Canada. tmengl@mmm.com
SOURCE: Antimicrobial Agents and Chemotherapy, (2003) Vol. 47, No. 12, pp. 3846-3852. .
Refs: 21
ISSN: 0066-4804 CODEN: AMACCQ
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 004 Microbiology
026 Immunology, Serology and Transplantation
030 Pharmacology
037 Drug Literature Index
039 Pharmacy
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 20040116
Last Updated on STN: 20040116

L1 ANSWER 15 OF 16 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults.
AB Resiquimod is a Toll-like receptor 7 (TLR7) and **TLR8 agonist** that is a potent inducer of alpha interferon (IFN-alpha) and other cytokines. The effects of multiple applications of resiquimod gel were assessed in a randomized, single-blind, dose-ranging, placebo-controlled study with 41 healthy subjects. Over a 3-week period, 1-g doses of resiquimod or vehicle gel (3:1 randomization) were applied to

a 50-cm² area of the upper arm according to the following regimens: 0.25% applied for 8 h two times per week, 0.05% applied for 8 h two times per week, 0.05% applied for 8 h three times per week, and 0.01% applied for 24 h three times per week. Skin biopsy specimens were obtained prior to the application of the first dose and after the completion of application of the last dose. Dosing with 0.01 and 0.05% resiquimod was well tolerated, but that with 0.25% was not; a dose-response relationship for local adverse effects was observed. The level of systemic exposure during multiple topical dosings was <1% of the applied dose. A significant increase in responders after completion of application of the last dose was observed for serum IFN and the interleukin-1 (IL-1) receptor antagonist (P < 0.01, Fisher's exact test). Increased levels of mRNA for IL-6, IL-8, IFN-alpha, and Mx (an IFN-alpha-inducible protein) were seen in posttreatment biopsy specimens from the group receiving 0.25% resiquimod compared to the levels seen in specimens from the group receiving vehicle only (P < 0.01, Wilcoxon rank sum test). A dose-response-related increase in CD3-positive cells consistent with T-lymphocyte infiltration and a decrease in CD1a-positive cells, consistent with emigration of Langerhans' cells, were observed in treated skin. This study suggests that resiquimod is a potent topically active immune response modifier that significantly enhances the cutaneous immune response.

ACCESSION NUMBER: 2004:22810 BIOSIS
DOCUMENT NUMBER: PREV200400010120
TITLE: Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults.
AUTHOR(S): Sauder, Daniel N.; Smith, Michael H.; Senta-McMillian, Therese; Soria, Inmaculada; Meng, Tze-Chiang [Reprint Author]
CORPORATE SOURCE: 3M Pharmaceuticals, 3M Center, 275-2W-14, Saint Paul, MN, 55144-1000, USA
tmengl@mmm.com
SOURCE: Antimicrobial Agents and Chemotherapy, (December 2003) Vol. 47, No. 12, pp. 3846-3852. print.
ISSN: 0066-4804 (ISSN print).
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 24 Dec 2003
Last Updated on STN: 24 Dec 2003

L1 ANSWER 16 OF 16 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
TI Generating an immune response in a subject against an antigen by topically administering a Toll-like receptor 8 (TLR8) agonist immune response modifier (IRM) compound and a pharmaceutical composition comprising the antigen; plasmid-mediated antigen gene transfer and expression in human cell for use in bacterium, virus or fungus infection nucleic acid vaccine and gene therapy
AN 2005-11694 BIOTECHDS
AB DERWENT ABSTRACT:
NOVELTY - Generating an immune response in a subject against an antigen comprises topically administering a Toll-like receptor 8 (TLR8) agonist immune response modifier (IRM) compound to an administration site of the subject to potentiate an immune response to an antigen and administering at the administration site a pharmaceutical composition comprising the antigen to generate an immune response to the antigen.
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following: (1) a method of increasing an immune response raised by a subject in response to administering a vaccine at a vaccination site; (2) a pharmaceutical combination comprising a component that comprises an antigen and a topical formulation that comprises TLR8

agonist, or its pharmaceutically acceptable form; and (3) a kit comprising a first container that contains a pharmaceutical composition that includes an antigen and a second container that includes an IRM compound, or its pharmaceutically acceptable form.

BIOTECHNOLOGY - Preferred Method: Generating an immune response in a subject against an antigen comprises topically administering a Toll-like receptor 8 (**TLR8**) **agonist** immune response modifier (IRM) compound to an administration site of the subject to potentiate an immune response to an antigen and administering at the administration site a pharmaceutical composition comprising the antigen to generate an immune response to the antigen. The IRM compound comprises a TLR7/8 agonist. The IRM compound is a TLR8-selective agonist. The IRM compound comprises an imidazoquinoline amine, tetrahydroimidazoquinoline amine, an imidazopyridine amine, a 1,2-bridged imidazoquinoline amine, a 6,7-fused cycloalkylimidazopyridine amine, an imidazonaphthyridine amine, a tetrahydroimidazonaphthyridine amine, an oxazoloquinoline amine, a thiazoloquinoline amine, an oxazolopyridine amine, a thiazolopyridine amine, an oxazolophthyridine amine, or a thiazolophthyridine amine. The pharmaceutical composition comprises a vaccine. The antigen comprises a bacterial antigen, a viral antigen, a fungal antigen or a tumor-derived antigen. The antigen comprises a peptide or polypeptide. The antigen is provided as a nucleic acid, at least a portion of which encodes the peptide or polypeptide. The antigen comprises a prion, a live or inactivated bacterium, a live or inactivated virus, or a live or inactivated fungus. The IRM compound is administered before the pharmaceutical composition is administered. The IRM compound is administered at least twice prior to administration of the pharmaceutical composition. The IRM compound is administered before at least one administration of the pharmaceutical composition. The immune response comprises a Th1 immune response. The pharmaceutical composition is administered at least twice. Increasing an immune response raised by a subject in response to administering a vaccine at a vaccination site comprises topically administering the **TLR8 agonist** IRM compound to the subject at the vaccination site. The vaccine comprises a bacterial antigen, a viral antigen, a fungal antigen, or a tumor-derived antigen. The vaccine comprises an antigen that comprises a peptide or a polypeptide. The antigen is provided as a nucleic acid, at least a portion of which encodes the peptide or polypeptide. The vaccine comprises a prion, a live or inactivated bacterium, a live or inactivated virus, or a live or inactivated fungus. The IRM compound is administered before the vaccine is administered. The IRM compound is administered at least twice. The IRM compound is administered at least twice prior to administering the vaccine. The immune response comprises a TH1 immune response. The vaccine is administered at least twice. The IRM compound is administered before at least one administration of the vaccine. Preferred Composition: The **TLR8 agonist** is a TLR7/8 agonist, or its pharmaceutically acceptable form. The component that comprises an antigen is a vaccine.

ACTIVITY - Antibacterial; Virucide; Cytostatic; Fungicide; Immunostimulant. No biological data given.

MECHANISM OF ACTION - Vaccine.

USE - The method is useful in generating an immune response in a subject against bacterial, viral, fungal or tumor-derived antigen (claimed).

ADMINISTRATION - Dosage comprises 10ng to 50mg per kg body weight.

The composition is administered via topical route (claimed). (16 pages)

ACCESSION NUMBER: 2005-11694 BIOTECHDS

TITLE: Generating an immune response in a subject against an antigen by topically administering a Toll-like receptor 8 (**TLR8**) **agonist** immune response modifier (IRM) compound and a pharmaceutical composition comprising the antigen;
plasmid-mediated antigen gene transfer and expression in

human cell for use in bacterium, virus or fungus infection
nucleic acid vaccine and gene therapy

AUTHOR: KEDL R M; TOMAI M A; VASILAKOS J P
PATENT ASSIGNEE: 3M INNOVATIVE PROPERTIES CO
PATENT INFO: US 2005048072 3 Mar 2005
APPLICATION INFO: US 2004-925473 25 Aug 2004
PRIORITY INFO: US 2004-925473 25 Aug 2004; US 2003-497628 25 Aug 2003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: WPI: 2005-202050 [21]

=> d his

(FILE 'HOME' ENTERED AT 12:20:48 ON 12 MAR 2006)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, BIOSIS, BIOTECHDS, FSTA,
JICST-EPLUS' ENTERED AT 12:21:10 ON 12 MAR 2006

L1 16 S (TLR8 AGONIST)

=> e gorden, k/au

E1	1	GORDEN WAGENER/AU
E2	1	GORDEN WILLIAM/AU
E3	0 -->	GORDEN, K/AU
E4	1	GORDENCHUK V D/AU
E5	4	GORDENCHUK V G/AU
E6	1	GORDENI D A/AU
E7	4	GORDENIN D/AU
E8	85	GORDENIN D A/AU
E9	1	GORDENIN D D/AU
E10	3	GORDENIN DMITRY/AU
E11	29	GORDENIN DMITRY A/AU
E12	10	GORDENINA T I/AU

=> s imidazopyridine amine

L2 58 IMIDAZOPYRIDINE AMINE

=> a (substituted imidazoquinoline amine)

A IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s (substituted imidazoquinoline amine)

L3 27 (SUBSTITUTED IMIDAZOQUINOLINE AMINE)

=> s l2 and l3

L4 27 L2 AND L3

=> d l4 ti abs ibib tto

'TTO' IS NOT A VALID FORMAT

In a multifile environment, a format can only be used if it is valid
in at least one of the files. Refer to file specific help messages
or the STNGUIDE file for information on formats available in
individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):end

=> d l4 ti abs ibib tot

L4 ANSWER 1 OF 27 USPATFULL on STN

TI Compositions and methods for mucosal vaccination

AB The present invention provides pharmaceutical combinations that include
an IRM compound formulated for mucosal administration and an antigen

formulated for mucosal administration. Additionally, the invention provides methods for immunizing a subject. Generally, the methods include administering an antigen to a mucosal surface of the subject in an amount effective, in combination with an IRM compound, to generate an immune response against the antigen; and administering an IRM compound to a mucosal surface of the subject in an amount effective, in combination with the antigen, to generate an immune response against the antigen.

ACCESSION NUMBER: 2006:60209 USPATFULL
TITLE: Compositions and methods for mucosal vaccination
INVENTOR(S): Miller, Richard L., Maplewood, MN, UNITED STATES
Kieper, William C., Stillwater, MN, UNITED STATES
PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006051374	A1	20060309
APPLICATION INFO.:	US 2005-116476	A1	20050428 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-566121P	20040428 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427, US	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	976	

L4 ANSWER 2 OF 27 USPATFULL on STN
TI HIV immunostimulatory compositions
AB The present invention provides an IRM-HIV composition that includes an IRM portion paired with an HIV antigenic portion.

ACCESSION NUMBER: 2006:53585 USPATFULL
TITLE: HIV immunostimulatory compositions
INVENTOR(S): Kedl, Ross M., Denver, CO, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006045886	A1	20060302
APPLICATION INFO.:	US 2005-213405	A1	20050826 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-604903P	20040827 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427, US	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	879	

L4 ANSWER 3 OF 27 USPATFULL on STN
TI Method of eliciting an immune response against HIV
AB The present invention provides methods of eliciting an immune response against HIV. Generally, the method includes administering to a subject an effective amount of an IRM-HIV composition that includes an IRM

portion paired with an HIV antigenic portion.

ACCESSION NUMBER: 2006:53584 USPATFULL
TITLE: Method of eliciting an immune response against HIV
INVENTOR(S): Kedl, Ross M., Denver, CO, UNITED STATES
Seder, Robert A., Bethesda, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006045885	A1	20060302
APPLICATION INFO.:	US 2005-213354	A1	20050826 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-605187P	20040827 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427, US	
NUMBER OF CLAIMS:	38	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	997	

L4 ANSWER 4 OF 27 USPATFULL on STN

TI Treatment for lung cancer

AB The present invention provides methods, pharmaceutical compositions, and pharmaceutical combinations useful for treating lung cancer. Generally, the compositions include a 5-LO inhibitor in an amount effective to inhibit 5-lipoxygenase in an inhalable formulation. In some cases, the formulation may further include an IRM compound. Generally, the pharmaceutical combinations include a 5-LO inhibitor and an IRM compound in an inhalable formulation. Generally, the methods include administering to the subject an inhalable formulation that comprises a 5-lipoxygenase inhibitor having a cLogP of at least about 4.0 in an amount effective for treating lung cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:306502 USPATFULL
TITLE: Treatment for lung cancer
INVENTOR(S): Merrill, Bryon A., River Falls, WI, UNITED STATES
Myrdal, Paul B., Tucson, AZ, UNITED STATES
Wightman, Paul D., Woodbury, MN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005267145	A1	20051201
APPLICATION INFO.:	US 2005-141655	A1	20050531 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-575496P	20040528 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427, US	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	907	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 27 USPATFULL on STN

TI Enhancement of immune responses
AB The present invention provides methods for enhancing the immune responses induced by IRM compounds. Generally, the methods include administering a cytokine receptor agonist or a cytokine inducer prior to administering an IRM compound to a cell population.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:275172 USPATFULL
TITLE: Enhancement of immune responses
INVENTOR(S): Miller, Richard L., Maplewood, MN, UNITED STATES
Tomai, Mark A., Woodbury, MN, UNITED STATES
PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005239735	A1	20051027
APPLICATION INFO.:	US 2004-27037	A1	20041230 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-533143P	20031230 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427, US	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
LINE COUNT:	864	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 27 USPATFULL on STN

TI Therapeutic combinations and methods including IRM compounds
AB The present invention provides therapeutic combinations that include an immune response modifier (IRM) component and an anti-inflammatory component. The inventions further provide methods of treating a condition by administering to one having the condition a therapeutic combination that includes an IRM component and an anti-inflammatory component.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:260857 USPATFULL
TITLE: Therapeutic combinations and methods including IRM compounds
INVENTOR(S): Tomai, Mark A., Woodbury, MN, UNITED STATES
Gullikson, Gary W., Stillwater, MN, UNITED STATES
Hammerbeck, David M., Houlton, WI, UNITED STATES
Egging, Elaine A., Woodbury, MN, UNITED STATES
Reiter, Michael J., New Richmond, WI, UNITED STATES
Gram, Christopher D., River Falls, WI, UNITED STATES
Vasilakos, John P., Woodbury, MN, UNITED STATES
Alkan, Sefik S., Woodbury, MN, UNITED STATES
PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005226878	A1	20051013
APPLICATION INFO.:	US 2005-142045	A1	20050601 (11)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2004-1979, filed on 2 Dec 2004, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-526240P	20031202 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: 3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST.
PAUL, MN, 55133-3427, US
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 1254
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 27 USPATFULL on STN
TI Therapeutic combinations and methods including IRM compounds
AB The present invention provides therapeutic combinations that include an immune response modifier (IRM) component and an anti-inflammatory component. The inventions further provide methods of treating a condition by administering to one having the condition a therapeutic combination that includes an IRM component and an anti-inflammatory component.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:196929 USPATFULL
TITLE: Therapeutic combinations and methods including IRM compounds
INVENTOR(S): Tomai, Mark A., Woodbury, MN, UNITED STATES
Gullikson, Gary W., Stillwater, MN, UNITED STATES
Hammerbeck, David M., Houlton, WI, UNITED STATES
Egging, Elaine A., Woodbury, MN, UNITED STATES
Reiter, Michael J., New Richmond, WI, UNITED STATES
Gram, Christopher D., River Falls, WI, UNITED STATES
Vasilakos, John P., Woodbury, MN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005171072	A1	20050804
APPLICATION INFO.:	US 2004-1979	A1	20041202 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-526240P	20031202 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: 3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST.
PAUL, MN, 55133-3427, US
NUMBER OF CLAIMS: 64
EXEMPLARY CLAIM: 1
LINE COUNT: 1237
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 8 OF 27 USPATFULL on STN
TI Method of treating scarring
AB Methods of treating scarring are disclosed. Generally, the methods include topically administering an IRM compound to the site of a surgical wound for a period of time and in an amount effective for preventing, reversing, or reducing the formation of a scar. Suitable IRM compound compounds include agonists of one or more TLRs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:190127 USPATFULL
TITLE: Method of treating scarring
INVENTOR(S): Miller, Richard L., Maplewood, MN, UNITED STATES
Lee, James H., St. Paul, MN, UNITED STATES
Owens, Mary L., Cottage Grove, MN, UNITED STATES
PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005165043	A1	20050728
APPLICATION INFO.:	US 2005-91037	A1	20050328 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2004-799999, filed on 12 Mar 2004, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-454245P	20030313 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427, US	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
LINE COUNT:	779	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L4 ANSWER 9 OF 27 USPATFULL on STN

TI Immunomodulatory combinations

AB The present invention provides immunomodulatory combinations that includes an IRM component and a therapeutic agent, each in an amount that, when in combination with the other, is effective for inducing an immune response in a subject.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:182942 USPATFULL

TITLE: Immunomodulatory combinations

INVENTOR(S): Hammerbeck, David M., Houlton, WI, UNITED STATES
Kedl, Ross M., Denver, CO, UNITED STATES
Miller, Richard L., Maplewood, MN, UNITED STATES
Tomai, Mark A., Woodbury, MN, UNITED STATES
Vasilakos, John P., Woodbury, MN, UNITED STATES

PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005158325	A1	20050721
APPLICATION INFO.:	US 2004-26457	A1	20041230 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-533179P	20031230 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427, US	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	3639	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L4 ANSWER 10 OF 27 USPATFULL on STN

TI Neutrophil activation by immune response modifier compounds

AB The invention provides a method of activating neutrophils. Generally, the method includes contacting neutrophils with a neutrophil-activating IRM compound and/or a TLR8-selective agonist in an amount effective to activate the neutrophils. In some embodiments, the method may be used to treat a condition treatable by activating neutrophils. In another aspect, the invention provides pharmaceutical compositions that

generally include a neutrophil-activating IRM compound and/or a TLR8-selective agonist, or a pharmaceutically acceptable form thereof, in an amount effective to activate neutrophils.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:112175 USPATFULL
TITLE: Neutrophil activation by immune response modifier compounds
INVENTOR(S): Tomai, Mark A., Woodbury, MN, UNITED STATES
Vasilakos, John P., Woodbury, MN, UNITED STATES
Wightman, Paul D., Woodbury, MN, UNITED STATES
PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005096259	A1	20050505
APPLICATION INFO.:	US 2004-978850	A1	20041101 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-516116P	20031031 (60)
	US 2003-517805P	20031106 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427, US	
NUMBER OF CLAIMS:	46	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	796	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 11 OF 27 USPATFULL on STN

TI Infection prophylaxis using immune response modifier compounds
AB The present invention provides methods of providing prophylaxis to a subject against an infectious agent. In general, the methods include topically administering to the respiratory tract of a subject an IRM compound in an amount effective to reduce infection by the agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:82013 USPATFULL
TITLE: Infection prophylaxis using immune response modifier compounds
INVENTOR(S): Hammerbeck, David M., Houlton, WI, UNITED STATES
Guy, Cynthia A., Little Canada, MN, UNITED STATES
PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005070460	A1	20050331
APPLICATION INFO.:	US 2004-911800	A1	20040805 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-493109P	20030805 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	867	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 12 OF 27 USPATFULL on STN

TI Selective modulation of TLR gene expression

AB The present invention provides a method of identifying a compound that selectively modulates expression of at least one TLR gene. Generally, the method includes providing an assay to detect expression of each of a plurality of TLR genes; performing each assay using a test compound; and identifying the test compound as a compound that selectively modulates expression of at least one TLR gene if the test compound modulates expression of a first TLR gene to a different extent than it modulates expression of at least one second TLR gene. In certain embodiments, the present invention provides compounds identified by a method described above, salts thereof, and pharmaceutical compositions including such compounds, pharmaceutically acceptable forms thereof, derivatives thereof, or pro-drugs thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:68933 USPATFULL

TITLE: Selective modulation of TLR gene expression

INVENTOR(S): Birmachu, Woubalem M. R., St. Anthony Village, MN, UNITED STATES

Burger, Marla J. C., Woodbury, MN, UNITED STATES

Gleason, Raymond M., Eagan, MN, UNITED STATES

Hanten, John A., Cottage Grove, MN, UNITED STATES

Jin, Jizhong, Vadnais Heights, MN, UNITED STATES

PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005059072	A1	20050317
APPLICATION INFO.:	US 2004-944291	A1	20040917 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-503566P	20030917 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	1133	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 13 OF 27 USPATFULL on STN

TI Treatment for CD5+ B cell lymphoma

AB The present invention provides methods for increasing expression of cell surface molecules of CD5^{sup.}+ B cell lymphoma cells by contacting cells with immune response modifiers. The invention also provides methods for the treatment of CD5^{sup.}+ B cell lymphomas, including chronic lymphocytic leukemia and small lymphocytic lymphoma, by administering immune response modifier compounds to a subject in need of such treatment. Suitable immune response modifier compounds include agonists of TLR7 and/or TLR8.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:63623 USPATFULL

TITLE: Treatment for CD5+ B cell lymphoma

INVENTOR(S): Miller, Richard L., Maplewood, MN, UNITED STATES

Spaner, David E., Toronto, CANADA

PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005054665	A1	20050310
APPLICATION INFO.:	US 2004-933594	A1	20040903 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-500478P	20030905 (60)
	US 2004-561440P	20040412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427	
NUMBER OF CLAIMS:	67	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Page(s)	
LINE COUNT:	1365	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 14 OF 27 USPATFULL on STN

TI Immunostimulatory combinations and treatments

AB The present invention provides immunostimulatory combinations and methods. Generally, the immunostimulatory combinations include a topical formulation of an IRM compound and a pharmaceutical composition. Generally, the methods include administering (a) a topical formulation of an IRM compound, and (b) a pharmaceutical composition to an administration site of a subject.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:56161 USPATFULL

TITLE: Immunostimulatory combinations and treatments

INVENTOR(S): Kedl, Ross M., Denver, CO, UNITED STATES
Tomai, Mark A., Woodbury, MN, UNITED STATES
Vasilakos, John P., Woodbury, MN, UNITED STATES

PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005048072	A1	20050303
APPLICATION INFO.:	US 2004-925473	A1	20040825 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-497628P	20030825 (60)
	US 2003-524213P	20031121 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427	
NUMBER OF CLAIMS:	75	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	1097	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 15 OF 27 USPATFULL on STN

TI Compositions and methods for induction of opioid receptors

AB The present invention provides compositions and method for increasing expression of opioid receptors. Generally, the compositions include and opioid receptor inducing compound and, optionally, an opioid receptor ligand. Generally, the methods include contacting a cell with an amount of an opioid receptor inducing compound effective for inducing

expression of the opioid receptor and, optionally, contacting the cell with an opioid receptor ligand.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:274349 USPATFULL
TITLE: Compositions and methods for induction of opioid receptors
INVENTOR(S): Birmachu, Woubalem M.R., St. Anthony Village, MN, UNITED STATES
Slade, Herbert B., Woodbury, MN, UNITED STATES
Stolpa, John C., St. Paul, MN, UNITED STATES
Urosevic, Mirjana, Zurich, SWITZERLAND
PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004214851	A1	20041028
APPLICATION INFO.:	US 2004-832737	A1	20040427 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-466227P	20030428 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427	
NUMBER OF CLAIMS:	39	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	1187	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 16 OF 27 USPATFULL on STN
TI Delivery of immune response modifier compounds using metal-containing particulate support materials
AB The present invention provides immune response modifiers (IRMs) on particulate support materials that includes one or more metals, including alloys or complexes thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:260225 USPATFULL
TITLE: Delivery of immune response modifier compounds using metal-containing particulate support materials
INVENTOR(S): Wightman, Paul D., Woodbury, MN, UNITED STATES
Liu, Jie J., Woodbury, MN, UNITED STATES
Jing, Naiyong, Woodbury, MN, UNITED STATES
PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004202720	A1	20041014
APPLICATION INFO.:	US 2004-821319	A1	20040409 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-640904, filed on 14 Aug 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-462140P	20030410 (60)
	US 2004-545542P	20040218 (60)
	US 2003-515256P	20031029 (60)
	US 2004-545424P	20040218 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

LEGAL REPRESENTATIVE: 3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST.
PAUL, MN, 55133-3427
NUMBER OF CLAIMS: 60
EXEMPLARY CLAIM: 1
LINE COUNT: 1759
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 17 OF 27 USPATFULL on STN

TI Selective activation of cellular activities mediated through a common
toll-like receptor

AB Methods of identifying compounds that selectively modulate cellular
activities mediated by a common TLR are provided. Generally, the methods
include providing an assay to detect modulation of a first cellular
activity mediated by a TLR; providing an assay to detect modulation of a
second cellular activity mediated by the TLR; performing each assay
using a test compound; and identifying the test compound as a compound
that selectively modulates at least one cellular activity of a plurality
of activities mediated by a common TLR if the test compound modulates
the first cellular activity to a different extent than it modulates the
second TLR-mediated cellular activity. Compounds identified by such
methods, pharmaceutical compositions including such compounds, and
methods of treating a condition by administering such pharmaceutical
compositions to a subject are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:247238 USPATFULL
TITLE: Selective activation of cellular activities mediated
through a common toll-like receptor
INVENTOR(S): Fink, Jason R., Eagan, MN, UNITED STATES
Gupta, Shalley K., Woodbury, MN, UNITED STATES
PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004191833	A1	20040930
APPLICATION INFO.:	US 2004-807934	A1	20040324 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-457336P	20030325 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1382	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 18 OF 27 USPATFULL on STN

TI Method of tattoo removal

AB A method for removing tattoos is disclosed. Generally, the method
includes administering an IRM compound to the tattooed region. In some
cases, the method also includes treating a tattooed area with a cell
disrupter such as a laser beam.

ACCESSION NUMBER: 2004:234136 USPATFULL
TITLE: Method of tattoo removal
INVENTOR(S): Graham, Paul D., Woodbury, MN, UNITED STATES
Elliott, Peter T., Woodbury, MN, UNITED STATES
Gallagher, Kevin G., Minneapolis, MN, UNITED STATES
PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004181211	A1	20040916
APPLICATION INFO.:	US 2004-799960	A1	20040312 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-454246P	20030313 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	674	

L4 ANSWER 19 OF 27 USPATFULL on STN
 TI Methods for diagnosing skin lesions
 AB Methods for diagnosing skin lesions are disclosed. Generally, the method include topically administering an IRM compound to a treatment area for a period of time and in an amount effective to cause a visible change in the appearance of a skin lesion including, in some cases, causing subclinical lesions to become visible. Suitable IRM compounds include agonists of one or more TLRs.

ACCESSION NUMBER: 2004:234056 USPATFULL
 TITLE: Methods for diagnosing skin lesions
 INVENTOR(S): Miller, Richard L., Maplewood, MN, UNITED STATES
 Lee, James H., St. Paul, MN, UNITED STATES
 Fox, Terrance L., Oakdale, MN, UNITED STATES
 PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004181130	A1	20040916
APPLICATION INFO.:	US 2004-799997	A1	20040312 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-454244P	20030313 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427	
NUMBER OF CLAIMS:	30	
EXEMPLARY CLAIM:	1	
LINE COUNT:	852	

L4 ANSWER 20 OF 27 USPATFULL on STN
 TI Methods of improving skin quality
 AB Methods of improving skin quality are disclosed. Generally, the methods include topically administering an IRM compound to a treatment area of skin for a period of time and in an amount effective for improving the quality of the skin. Suitable IRM compound compounds include agonists of one or more TLRs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:233845 USPATFULL
 TITLE: Methods of improving skin quality
 INVENTOR(S): Miller, Richard L., Maplewood, MN, UNITED STATES
 Lee, James H., St. Paul, MN, UNITED STATES
 Owens, Mary L., Cottage Grove, MN, UNITED STATES

PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004180919	A1	20040916
APPLICATION INFO.:	US 2004-799999	A1	20040312 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-454245P	20030313 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
LINE COUNT:	801	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 21 OF 27 USPATFULL on STN
TI Prophylactic treatment of UV-induced epidermal neoplasia
AB The present invention provides a method of protecting a subject against UV-induced epidermal neoplasia. Generally, the method includes administering to a subject an IRM compound in an amount effective to provide protection against UV-induced epidermal neoplasia. The present invention also provides compositions that include an IRM compound in an amount effective for providing protection against UV-induced epidermal neoplasia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:226951 USPATFULL
TITLE: Prophylactic treatment of UV-induced epidermal neoplasia
INVENTOR(S): Egging, Elaine A., Woodbury, MN, UNITED STATES
Hammerbeck, David M., Houlton, WI, UNITED STATES
Lee, James H., St. Paul, MN, UNITED STATES
PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004175336	A1	20040909
APPLICATION INFO.:	US 2004-793293	A1	20040304 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-451699P	20030304 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
LINE COUNT:	917	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 22 OF 27 USPATFULL on STN
TI Selective modulation of TLR-mediated biological activity
AB Methods of identifying a compound that selectively modulates at least one TLR-mediated cellular activity are disclosed. Generally, the methods include identifying a compound as a compound that selectively modulates at least one TLR-mediated cellular activity if the compound modulates one TLR-mediated cellular activity to a different extent than it modulates a second TLR-mediated cellular activity. Compounds so

identified and pharmaceutical compositions including such compounds are also disclosed. Methods of selectively modulating immune cells and methods of treating certain conditions are also provided. Such methods include administering to cells or a subject a compound that selectively modulates a TLR-mediated cellular activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:221317 USPATFULL
TITLE: Selective modulation of TLR-mediated biological activity
INVENTOR(S): Fink, Jason R., Eagan, MN, UNITED STATES
Gorden, Keith B., Maplewood, MN, UNITED STATES
Gorski, Kevin S., White Bear Lake, MN, UNITED STATES
Gupta, Shalley K., Woodbury, MN, UNITED STATES
Qiu, Xiaohong, Rosemount, MN, UNITED STATES
Vasilakos, John P., Woodbury, MN, UNITED STATES
PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004171086	A1	20040902
APPLICATION INFO.:	US 2004-788731	A1	20040227 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-450484P	20030227 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427	
NUMBER OF CLAIMS:	55	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	1870	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 23 OF 27 USPATFULL on STN
TI Methods and compositions related to IRM compounds and toll-like receptor 8
AB Methods of eliciting a TLR8-mediated cellular response are disclosed. Such methods include administration of either a TLR8 agonist or a TLR8 antagonist to an IRM-responsive cell so that the IRM compound affects at least one TLR8-mediate cellular signaling pathway. In some cases, the method may provide prophylactic or therapeutic treatment for a condition treatable by modulating a TLR8-mediated cellular pathway.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:209875 USPATFULL
TITLE: Methods and compositions related to IRM compounds and toll-like receptor 8
INVENTOR(S): Gorden, Keith B., Maplewood, MN, UNITED STATES
Qiu, Xiaohong, Rosemount, MN, UNITED STATES
Vasilakos, John P., Woodbury, MN, UNITED STATES
PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004162309	A1	20040819
APPLICATION INFO.:	US 2004-777310	A1	20040212 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-447179P	20030213 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: 3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST.
PAUL, MN, 55133-3427

NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 1684
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 24 OF 27 USPATFULL on STN
TI Immunostimulatory combinations
AB The present invention provides immunostimulatory combinations.
Generally, the immunostimulatory combinations include a TLR agonist and
a TNF/R agonist. Certain immunostimulatory combinations also may include
an antigen.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:184067 USPATFULL
TITLE: Immunostimulatory combinations
INVENTOR(S): Noelle, Randolph J., Plainfield, NH, UNITED STATES
Ahonen, Cory L., Hanover, NH, UNITED STATES
Kedl, Ross M., Roseville, MN, UNITED STATES
PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004141950	A1	20040722
APPLICATION INFO.:	US 2003-748010	A1	20031230 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-437398P	20021230 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: 3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST.
PAUL, MN, 55133-3427
NUMBER OF CLAIMS: 57
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 1355
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 25 OF 27 USPATFULL on STN
TI Methods and compositions related to IRM compounds and toll-like receptor
pathways
AB Methods for identifying a compound that activates a TLR-mediated
cellular signaling pathway is disclosed. The method includes (a)
exposing a TLR-positive cell culture to a test compound and measuring a
TLR-mediated cellular response; (b) exposing a TLR-negative cell culture
to a test compound and measuring a TLR-mediated cellular response; and
(c) identifying the test compound as an IRM if the cellular response in
the TLR-positive cell culture is greater than the cellular response of
the TLR-negative cell culture. Methods of eliciting a TLR-mediated
cellular response are also disclosed. Such methods include
administration of an IRM compound to an IRM-responsive cell so that the
IRM compounds affects at least one TLR-mediate cellular signaling
pathway.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:19475 USPATFULL
TITLE: Methods and compositions related to IRM compounds and
toll-like receptor pathways

INVENTOR(S): Gorden, Keith B., Maplewood, MN, UNITED STATES
Qiu, Xiaohong, Rosemount, MN, UNITED STATES
Tomai, Mark A., Woodbury, MN, UNITED STATES
Vasilakos, John P., St. Paul, MN, UNITED STATES
PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014779	A1	20040122
APPLICATION INFO.:	US 2002-294935	A1	20021114 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-332412P	20011116 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427	
NUMBER OF CLAIMS:	59	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2101	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 26 OF 27 USPATFULL on STN
TI Method of reducing and treating UVB-induced immunosuppression
AB Methods of preventing and/or treating UV-induced immunosuppression by administration of immune response modifier compounds are disclosed herein. Suitable immune response modifier compounds include agonists of one or more TLRs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:231599 USPATFULL
TITLE: Method of reducing and treating UVB-induced immunosuppression
INVENTOR(S): Miller, Richard L., Maplewood, MN, UNITED STATES
Gaspari, Anthony A., Cockeysville, MD, UNITED STATES
Gillis, Joseph A., Eagan, MN, UNITED STATES
PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003161797	A1	20030828
APPLICATION INFO.:	US 2003-371146	A1	20030220 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-358982P	20020222 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	342	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 27 OF 27 DGENE COPYRIGHT 2006 The Thomson Corp on STN
TI Combination useful for the treatment of infectious diseases, cancer, asthma, allergy, warts comprises an immune response modifier and a therapeutic agent.
AN AEB54546 DNA DGENE
AB The invention relates to an immunomodulatory combination comprising an

immune response modifier (IRM) component and a therapeutic agent selected from a cancer antigen or a cancer antibody, an antigen of an infectious agent or a medicament. The IRM component is an imidazonaphthyridine amine, tetrahydroimidazonaphthyridine amine, oxazoloquinoline amine, thiazoloquinoline amine, oxazolopyridine amine, thiazolopyridine amine, oxazolonaphthyridine amine or a thiazolonaphthyridine amine (preferably imidazonaphthyridine amine, tetrahydroimidazonaphthyridine amine, oxazolonaphthyridine amine or a thiazolonaphthyridine amine). Also described is a combination comprising an IRM component and a therapeutic agent. The IRM component is a sulfonamide substituted imidazoquinoline amine, ether substituted imidazoquinoline amine, sulfonamide substituted tetrahydroimidazoquinoline amine, ether substituted tetrahydroimidazoquinoline amine, sulfonamide substituted imidazopyridine amine or an ether substituted imidazopyridine amine. The immunomodulatory combination of the invention is useful for the treatment of TH2 mediated diseases e.g. infectious diseases (caused by bacteria, virus, fungi and parasites), cancer, allergic diseases, bovine spongiform encephalopathy (mad cow disease), scrapie infection, Creutzfeldt-Jakob disease, neoplastic diseases (e.g. actinic keratosis, Kaposi's sarcoma etc), autoimmune diseases (e.g. atopic dermatitis or eczema, eosinophilia, asthma, systemic lupus erythematosus, essential thrombocythaemia, multiple sclerosis, Ommen's syndrome, discoid lupus, alopecia areata, keloid formation, scarring, wound healing (e.g. chronic wounds)). The infectious diseases include small pox, anthrax infections, influenza, warts, hepatitis B and C, HIV, measles, mumps, SARS, candidiasis, aspergillosis, histoplasmosis, cryptococcal meningitis, malaria, pneumocystis carinii pneumonia, leishmaniasis, cryptosporidiosis, toxoplasmosis and trypanosome. The allergic disorders include eczema, allergic rhinitis or coryza, hay fever, conjunctivitis, bronchial asthma, urticaria (hives), food allergy, atopic dermatitis, anaphylaxis, drug allergy, angioedema, allergic conjunctivitis, seasonal dermatitis, perennial dermatitis, rhinitis, allergic asthma, drug reactions and respiratory disorders. The immunomodulatory combination possesses potent immunomodulatory activity. The immunomodulatory combination provides long lasting effects, thus improving compliance and maintenance therapy, reducing emergency situations and improving quality of life. The immunomodulatory combination improves asthma control and normalizes lung function. This sequence represents a pan activating immunostimulatory nucleic acid that can be used in combination with the IRM compounds used in the invention.

ACCESSION NUMBER: AEB54546 DNA DGENE
 TITLE: Combination useful for the treatment of infectious diseases, cancer, asthma, allergy, warts comprises an immune response modifier and a therapeutic agent.
 INVENTOR: Hammerbeck D M; Kedl R M; Miller R L; Tomai M A; Vasilakos J P
 PATENT ASSIGNEE: (MINN)3M INNOVATIVE PROPERTIES CO.
 PATENT INFO: WO 2005065678 A1 20050721 97
 APPLICATION INFO: WO 2004-US43892 20041230
 PRIORITY INFO: US 2003-533179P 20031230
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 OTHER SOURCE: 2005-563725 [57]
 DESCRIPTION: Pan activating immunostimulatory nucleic acid #2006.

=> d his

(FILE 'HOME' ENTERED AT 12:20:48 ON 12 MAR 2006)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, BIOSIS, BIOTECHDS, FSTA,

JICST-EPLUS' ENTERED AT 12:21:10 ON 12 MAR 2006
L1 16 S (TLR8 AGONIST)
E GORDEN, K/AU
L2 58 S IMIDAZOPYRIDINE AMINE
L3 27 S (SUBSTITUTED IMIDAZOQUINOLINE AMINE)
L4 27 S L2 AND L3

=> s imidazonaphthyridine amine
L5 35 IMIDAZONAPHTHYRIDINE AMINE

=> d his

(FILE 'HOME' ENTERED AT 12:20:48 ON 12 MAR 2006)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, BIOSIS, BIOTECHDS, FSTA,
JICST-EPLUS' ENTERED AT 12:21:10 ON 12 MAR 2006
L1 16 S (TLR8 AGONIST)
E GORDEN, K/AU
L2 58 S IMIDAZOPYRIDINE AMINE
L3 27 S (SUBSTITUTED IMIDAZOQUINOLINE AMINE)
L4 27 S L2 AND L3
L5 35 S IMIDAZONAPHTHYRIDINE AMINE

=> s 15 and 12
L6 35 L5 AND L2

=> d 15 ti abs ibib 1-10

L5 ANSWER 1 OF 35 USPATFULL on STN
TI Compositions and methods for mucosal vaccination
AB The present invention provides pharmaceutical combinations that include an IRM compound formulated for mucosal administration and an antigen formulated for mucosal administration. Additionally, the invention provides methods for immunizing a subject. Generally, the methods include administering an antigen to a mucosal surface of the subject in an amount effective, in combination with an IRM compound, to generate an immune response against the antigen; and administering an IRM compound to a mucosal surface of the subject in an amount effective, in combination with the antigen, to generate an immune response against the antigen.

ACCESSION NUMBER: 2006:60209 USPATFULL
TITLE: Compositions and methods for mucosal vaccination
INVENTOR(S): Miller, Richard L., Maplewood, MN, UNITED STATES
Kieper, William C., Stillwater, MN, UNITED STATES
PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006051374	A1	20060309
APPLICATION INFO.:	US 2005-116476	A1	20050428 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-566121P	20040428 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427, US	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	976	

L5 ANSWER 2 OF 35 USPATFULL on STN
TI HIV immunostimulatory compositions
AB The present invention provides an IRM-HIV composition that includes an IRM portion paired with an HIV antigenic portion.

ACCESSION NUMBER: 2006:53585 USPATFULL
TITLE: HIV immunostimulatory compositions
INVENTOR(S): Kedl, Ross M., Denver, CO, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006045886	A1	20060302
APPLICATION INFO.:	US 2005-213405	A1	20050826 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-604903P	20040827 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427, US	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	879	

L5 ANSWER 3 OF 35 USPATFULL on STN
TI Method of eliciting an immune response against HIV
AB The present invention provides methods of eliciting an immune response against HIV. Generally, the method includes administering to a subject an effective amount of an IRM-HIV composition that includes an IRM portion paired with an HIV antigenic portion.

ACCESSION NUMBER: 2006:53584 USPATFULL
TITLE: Method of eliciting an immune response against HIV
INVENTOR(S): Kedl, Ross M., Denver, CO, UNITED STATES
Seder, Robert A., Bethesda, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006045885	A1	20060302
APPLICATION INFO.:	US 2005-213354	A1	20050826 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-605187P	20040827 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427, US	
NUMBER OF CLAIMS:	38	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	997	

L5 ANSWER 4 OF 35 USPATFULL on STN
TI Screening method for identifying compounds that selectively induce interferon alpha
AB Methods for screening for compounds that selectively induce IFN- α production and methods for ameliorating conditions in a patient using a small molecule that selectively induces the production of IFN- α are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:10629 USPATFULL
TITLE: Screening method for identifying compounds that
selectively induce interferon alpha
INVENTOR(S): Tomai, Mark A., Woodbury, MN, UNITED STATES
Vasilakos, John P., Woodbury, MN, UNITED STATES
PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006009482	A1	20060112
APPLICATION INFO.:	US 2005-220235	A1	20050906 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-13193, filed on 6 Dec 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-254229P	20001208 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427, US	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
LINE COUNT:	515	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 35 USPATFULL on STN

TI Treatment for lung cancer

AB The present invention provides methods, pharmaceutical compositions, and pharmaceutical combinations useful for treating lung cancer. Generally, the compositions include a 5-LO inhibitor in an amount effective to inhibit 5-lipoxygenase in an inhalable formulation. In some cases, the formulation may further include an IRM compound. Generally, the pharmaceutical combinations include a 5-LO inhibitor and an IRM compound in an inhalable formulation. Generally, the methods include administering to the subject an inhalable formulation that comprises a 5-lipoxygenase inhibitor having a cLogP of at least about 4.0 in an amount effective for treating lung cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:306502 USPATFULL
TITLE: Treatment for lung cancer
INVENTOR(S): Merrill, Bryon A., River Falls, WI, UNITED STATES
Myrdal, Paul B., Tucson, AZ, UNITED STATES
Wightman, Paul D., Woodbury, MN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005267145	A1	20051201
APPLICATION INFO.:	US 2005-141655	A1	20050531 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-575496P	20040528 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427, US	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	

LINE COUNT: 907
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 35 USPATFULL on STN

TI Methods and compositions related to IRM compounds and toll-like receptor pathways

AB Methods for identifying a compound that activates a TLR-mediated cellular signaling pathway is disclosed. The method includes (a) exposing a TLR-positive cell culture to a test compound and measuring a TLR-mediated cellular response; (b) exposing a TLR-negative cell culture to a test compound and measuring a TLR-mediated cellular response; and (c) identifying the test compound as an IRM if the cellular response in the TLR-positive cell culture is greater than the cellular response of the TLR-negative cell culture. Methods of eliciting a TLR-mediated cellular response are also disclosed. Such methods include administration of an IRM compound to an IRM-responsive cell so that the IRM compound affects at least one TLR-mediate cellular signaling pathway.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:281609 USPATFULL
TITLE: Methods and compositions related to IRM compounds and toll-like receptor pathways
INVENTOR(S): Gorden, Keith B., Maplewood, MN, UNITED STATES
Qiu, Xiaohong, Rosemount, MN, UNITED STATES
Tomai, Mark A., Woodbury, MN, UNITED STATES
Vasilakos, John P., Woodbury, MN, UNITED STATES
PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005245564	A1	20051103
APPLICATION INFO.:	US 2005-153059	A1	20050615 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-294935, filed on 14 Nov 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-332412P	20011116 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427, US	

NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
LINE COUNT: 1148
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 35 USPATFULL on STN

TI Enhancement of immune responses

AB The present invention provides methods for enhancing the immune responses induced by IRM compounds. Generally, the methods include administering a cytokine receptor agonist or a cytokine inducer prior to administering an IRM compound to a cell population.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:275172 USPATFULL
TITLE: Enhancement of immune responses
INVENTOR(S): Miller, Richard L., Maplewood, MN, UNITED STATES
Tomai, Mark A., Woodbury, MN, UNITED STATES
PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2005239735 A1 20051027
APPLICATION INFO.: US 2004-27037 A1 20041230 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-533143P	20031230 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427, US	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
LINE COUNT:	864	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 35 USPATFULL on STN

TI Therapeutic combinations and methods including IRM compounds
AB The present invention provides therapeutic combinations that include an immune response modifier (IRM) component and an anti-inflammatory component. The inventions further provide methods of treating a condition by administering to one having the condition a therapeutic combination that includes an IRM component and an anti-inflammatory component.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:260857 USPATFULL
TITLE: Therapeutic combinations and methods including IRM compounds
INVENTOR(S): Tomai, Mark A., Woodbury, MN, UNITED STATES
Gullikson, Gary W., Stillwater, MN, UNITED STATES
Hammerbeck, David M., Houlton, WI, UNITED STATES
Egging, Elaine A., Woodbury, MN, UNITED STATES
Reiter, Michael J., New Richmond, WI, UNITED STATES
Gram, Christopher D., River Falls, WI, UNITED STATES
Vasilakos, John P., Woodbury, MN, UNITED STATES
Alkan, Sefik S., Woodbury, MN, UNITED STATES
PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005226878	A1	20051013
APPLICATION INFO.:	US 2005-142045	A1	20050601 (11)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2004-1979, filed on 2 Dec 2004, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-526240P	20031202 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427, US	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	1254	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 9 OF 35 USPATFULL on STN

TI Therapeutic combinations and methods including IRM compounds
AB The present invention provides therapeutic combinations that include an immune response modifier (IRM) component and an anti-inflammatory

component. The inventions further provide methods of treating a condition by administering to one having the condition a therapeutic combination that includes an IRM component and an anti-inflammatory component.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:196929 USPATFULL
TITLE: Therapeutic combinations and methods including IRM compounds
INVENTOR(S): Tomai, Mark A., Woodbury, MN, UNITED STATES
Gullikson, Gary W., Stillwater, MN, UNITED STATES
Hammerbeck, David M., Houlton, WI, UNITED STATES
Egging, Elaine A., Woodbury, MN, UNITED STATES
Reiter, Michael J., New Richmond, WI, UNITED STATES
Gram, Christopher D., River Falls, WI, UNITED STATES
Vasilakos, John P., Woodbury, MN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005171072	A1	20050804
APPLICATION INFO.:	US 2004-1979	A1	20041202 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-526240P	20031202 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427, US	
NUMBER OF CLAIMS:	64	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1237	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 10 OF 35 USPATFULL on STN
TI Method of treating scarring
AB Methods of treating scarring are disclosed. Generally, the methods include topically administering an IRM compound to the site of a surgical wound for a period of time and in an amount effective for preventing, reversing, or reducing the formation of a scar. Suitable IRM compound compounds include agonists of one or more TLRs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:190127 USPATFULL
TITLE: Method of treating scarring
INVENTOR(S): Miller, Richard L., Maplewood, MN, UNITED STATES
Lee, James H., St. Paul, MN, UNITED STATES
Owens, Mary L., Cottage Grove, MN, UNITED STATES
PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005165043	A1	20050728
APPLICATION INFO.:	US 2005-91037	A1	20050328 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2004-799999, filed on 12 Mar 2004, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-454245P	20030313 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST.	

PAUL, MN, 55133-3427, US

NUMBER OF CLAIMS: 20

EXEMPLARY CLAIM: 1

LINE COUNT: 779

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Refine Search

Search Results -

Terms	Documents
L5 and L2	10

Database:

US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

L6

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Sunday, March 12, 2006 [Printable Copy](#) [Create Case](#)

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
<u>L6</u>	L5 and l2	10	<u>L6</u>
<u>L5</u>	L4 and l3	10	<u>L5</u>
<u>L4</u>	qiu.in.	4275	<u>L4</u>
<u>L3</u>	gorden.in.	262	<u>L3</u>
<u>L2</u>	Vasilakos.in.	49	<u>L2</u>
<i>DB=PGPB; PLUR=YES; OP=OR</i>			
<u>L1</u>	20050171072	1	<u>L1</u>

END OF SEARCH HISTORY

Hit List

[Clear](#) [Generate Collection](#) [Print](#) [Fwd Refs](#) [Bkwd Refs](#) [Generate OACS](#)

Search Results - Record(s) 1 through 10 of 10 returned.

☐ 1. Document ID: US 20050245564 A1

Using default format because multiple data bases are involved.

L6: Entry 1 of 10

File: PGPB

Nov 3, 2005

PGPUB-DOCUMENT-NUMBER: 20050245564

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050245564 A1

TITLE: Methods and compositions related to IRM compounds and toll-like receptor pathways

PUBLICATION-DATE: November 3, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
<u>Gorden</u> , Keith B.	Maplewood	MN	US
<u>Qiu</u> , Xiaohong	Rosemount	MN	US
Tomai, Mark A.	Woodbury	MN	US
<u>Vasilakos</u> , John P.	Woodbury	MN	US

US-CL-CURRENT: 514/292

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-----

☐ 2. Document ID: US 20040171086 A1

L6: Entry 2 of 10

File: PGPB

Sep 2, 2004

PGPUB-DOCUMENT-NUMBER: 20040171086

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040171086 A1

TITLE: Selective modulation of TLR-mediated biological activity

PUBLICATION-DATE: September 2, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Fink, Jason R.	Eagan	MN	US
<u>Gorden</u> , Keith B.	Maplewood	MN	US
Gorski, Kevin S.	White Bear Lake	MN	US
Gupta, Shalley K.	Woodbury	MN	US
<u>Qiu</u> , Xiaohong	Rosemount	MN	US
<u>Vasilakos</u> , John P.	Woodbury	MN	US

US-CL-CURRENT: 435/7.2; 514/1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-----

☐ 3. Document ID: US 20040162309 A1

L6: Entry 3 of 10

File: PGPB

Aug 19, 2004

PGPUB-DOCUMENT-NUMBER: 20040162309

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040162309 A1

TITLE: Methods and compositions related to IRM compounds and toll-like receptor 8

PUBLICATION-DATE: August 19, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
<u>Gorden</u> , Keith B.	Maplewood	MN	US
<u>Qiu</u> , Xiaohong	Rosemount	MN	US
<u>Vasilakos</u> , John P.	Woodbury	MN	US

US-CL-CURRENT: 514/292

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-----

☐ 4. Document ID: US 20040014779 A1

L6: Entry 4 of 10

File: PGPB

Jan 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040014779

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040014779 A1

TITLE: Methods and compositions related to IRM compounds and toll-like receptor pathways

PUBLICATION-DATE: January 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
<u>Gorden</u> , Keith B.	Maplewood	MN	US
<u>Qiu</u> , Xiaohong	Rosemount	MN	US
Tomai, Mark A.	Woodbury	MN	US
<u>Vasilakos</u> , John P.	St. Paul	MN	US

US-CL-CURRENT: 514/291; 514/292

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-----

☐ 5. Document ID: WO 2004075865 A2

L6: Entry 5 of 10

File: EPAB

Sep 10, 2004

PUB-NO: WO2004075865A2

DOCUMENT-IDENTIFIER: WO 2004075865 A2

TITLE: SELECTIVE MODULATION OF TLR-MEDIATED BIOLOGICAL ACTIVITY

PUBN-DATE: September 10, 2004

INVENTOR-INFORMATION:

NAME
FINK, JASON R
GORDEN, KEITH B
GORSKI, KEVIN S
GUPTA, SHALLEY K
QIU, XIAOHONG
VASILAKOS, JOHN P

COUNTRY

INT-CL (IPC): A61 K 0/
EUR-CL (EPC): A61K031/00; A61K031/44

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	NAME	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------	-----

☐ 6. Document ID: WO 2004071459 A2

L6: Entry 6 of 10

File: EPAB

Aug 26, 2004

PUB-NO: WO2004071459A2
DOCUMENT-IDENTIFIER: WO 2004071459 A2
TITLE: METHODS AND COMPOSITIONS RELATED TO IRM COMPOUNDS AND TOLL-LIKE RECEPTOR 8
PUBN-DATE: August 26, 2004

INVENTOR-INFORMATION:

NAME	COUNTRY
GORDEN, KEITH B	US
QIU, XIAOHONG	US
VASILAKOS, JOHN P	US

INT-CL (IPC): A61 K 0/
EUR-CL (EPC): A61K031/4745; G01N033/566

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	NAME	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------	-----

☐ 7. Document ID: WO 3043572 A2

L6: Entry 7 of 10

File: EPAB

May 30, 2003

PUB-NO: WO003043572A2
DOCUMENT-IDENTIFIER: WO 3043572 A2
TITLE: METHODS AND COMPOSITIONS RELATED TO IRM COMPOUNDS AND TOLL-LIKE RECEPTOR PATHWAYS
PUBN-DATE: May 30, 2003

INVENTOR-INFORMATION:

NAME	COUNTRY
GORDEN, KEITH B	
QIU, XIAOHONG	
TOMAI, MARK A	
VASILAKOS, JOHN P	

INT-CL (IPC): A61 K 0/
EUR-CL (EPC): A61K031/00; A61K031/4745, G01N033/68

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	NAME	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------	-----

☐ 8. Document ID: EP 1599726 A2, US 20040171086 A1, WO 2004075865 A2

L6: Entry 8 of 10

File: DWPI

Nov 30, 2005

DERWENT-ACC-NO: 2004-634546

DERWENT-WEEK: 200578

COPYRIGHT 2006 DERWENT INFORMATION LTD

TITLE: Identification of selective modulators of toll-like receptor mediated cellular activity that are useful for treating e.g. cancer involves detecting modulation of activities of several toll-like receptors by test compound

INVENTOR: FINK, J R; GORDEN, K B ; GORSKI, K S ; GUPTA, S K ; QIU, X ; VASILAKOS, J P

PRIORITY-DATA: 2003US-450484P (February 27, 2003), 2004US-0788731 (February 27, 2004)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>EP 1599726 A2</u>	November 30, 2005	E	000	G01N033/50
<u>US 20040171086 A1</u>	September 2, 2004		022	G01N033/53
<u>WO 2004075865 A2</u>	September 10, 2004	E	000	A61K000/00

INT-CL (IPC): A61 K 0/00; A61 K 31/44; A61 K 49/00; G01 N 33/50; G01 N 33/53; G01 N 33/567

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	-----------	-----

☐ 9. Document ID: EP 1592302 A2, US 20040162309 A1, WO 2004071459 A2

L6: Entry 9 of 10

File: DWPI

Nov 9, 2005

DERWENT-ACC-NO: 2004-624809

DERWENT-WEEK: 200573

COPYRIGHT 2006 DERWENT INFORMATION LTD

TITLE: Eliciting Toll-like receptor 8 mediated cellular response in cell that expresses Toll-like receptor 8 used for treating e.g. allergy or atopic dermatitis, comprises administering Toll-like receptor 8 agonist or antagonist to cell

INVENTOR: GORDEN, K B; QIU, X ; VASILAKOS, J P

PRIORITY-DATA: 2003US-447179P (February 13, 2003), 2004US-0777310 (February 12, 2004)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>EP 1592302 A2</u>	November 9, 2005	E	000	A01N043/90
<u>US 20040162309 A1</u>	August 19, 2004		025	A61K031/4745
<u>WO 2004071459 A2</u>	August 26, 2004	E	000	A61K000/00

INT-CL (IPC): A01 N 43/90; A61 K 0/00; A61 K 31/4745

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	-----------	-----

☐ 10. Document ID: AU 2002343728 A8, WO 2003043572 A2, US 20040014779 A1, AU 2002343728 A1, EP 1455700 A2, JP 2005513021 W, US 20050245564 A1

L6: Entry 10 of 10

File: DWPI

Oct 13, 2005

DERWENT-ACC-NO: 2003-532658

DERWENT-WEEK: 200611

COPYRIGHT 2006 DERWENT INFORMATION LTD

TITLE: Identifying immune response modifiers that activate Toll-like receptor, TLR-mediated cellular signaling pathway, by exposing test agent to TLR-positive and TLR-negative cell cultures and measuring cellular response

INVENTOR: GORDEN, K B; QIU, X ; TOMAI, M A ; VASILAKOS, J P

PRIORITY-DATA: 2001US-332412P (November 16, 2001), 2002US-0294935 (November 14, 2002), 2005US-0153059 (June 15, 2005)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>AU 2002343728 A8</u>	October 13, 2005		000	A61F013/02
<u>WO 2003043572 A2</u>	May 30, 2003	E	066	A61K000/00
<u>US 20040014779 A1</u>	January 22, 2004		000	A61K031/4745
<u>AU 2002343728 A1</u>	June 10, 2003		000	A61K000/00
<u>EP 1455700 A2</u>	September 15, 2004	E	000	A61F013/02
<u>JP 2005513021 W</u>	May 12, 2005		051	A61K045/00
<u>US 20050245564 A1</u>	November 3, 2005		000	A61K031/4745

INT-CL (IPC): A61 F 13/02; A61 K 0/00; A61 K 31/4745; A61 K 45/00; A61 P 11/02; A61 P 11/06; A61 P 17/04; A61 P 31/00; A61 P 31/04; A61 P 31/12; A61 P 35/00; A61 P 37/08; A61 P 43/00; C12 Q 1/02; G01 N 33/15; G01 N 33/50

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------	-----

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
L5 and L2	10

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)